Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET

European Journal of Cancer Part A

Volumn 33, Issue 8, 1997, Pages 1234-1241

  Nuutinen, J M ^a,b   Leskinen, S ^a,b   Elomaa, I ^c   Minn, H ^a,b   Varpula, M ^a   Solin, O ^d   Soderstrom K O ^a   Joensuu, H ^c   Salminen, E ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU PET CENTRE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Fluorodeoxyglucose; Positron emission tomography; Residual tumour; Testicular cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE DISSECTION; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; TESTIS CANCER;

ADULT; DEOXYGLUCOSE; DIAGNOSTIC ERRORS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0030852788     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00111-1     Document Type: Article

References (28)

1. Einhorn LH, Richie JP, Shipley WV. Cancer of testis. In DeVita, Hellman, Rosenberg, eds. Cancer Principles and Practise of Oncology. Philadelphia, J.B. Lippincott Co, 1993, 1126-1128.
2. United Kingdom Testicular Cancer Study Group. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility and exercise. Br Med J 1994, 28, 1393-1399.
3. Mustofi SK, Sobin LH. International Histological Classification of Tumors of Testes. Geneva, World Health Organization publications, 1977, No 16.
4. Einhorn LH. Salvage therapy for germ cell tumors. Semin Oncol (4) 1994, 21, 47-51.
5. Javadpour N, Young JD. Predictors of residual mass requiring resection after chemotherapy of stage III testicular cancer. A prospective study. Urology (1) 1992, 40, 7-8.
6. Bajorin D, Herr H, Motzer R, Bosl G. Current perspectives on the role of the adjuvant surgery in combined mortality treatment for patient with germ cell tumours. Semin Oncol 1992, 19, 148-158.
7. Stomper PC, Kalish LA, Garnick MB, Richie JP, Kantoff PW. CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous tumors: can residual malignancy or teratoma be excluded? Radiology (3) 1991, 180, 711-714.
8. Hendry WF. Decision making in abdominal surgery following chemotherapy for testicular cancer. Eur J Cancer (5) 1995, 31A, 649-650.
9. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991, 32, 623-648.
10. 18F)-2-deoxy-fluoro-D-glucose. J Nucl Med 1978, 19, 1154-1161.
11. Lapela M, Leskinen S, Minn H, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and flourine-18-fluorodeoxyglucose. Blood 1995, 86, 3522-3527.
12. 18F)fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987, 22, 360-371.
13. Alder LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991, 32, 1508-1512.
14. 18F)fluoro-2-deoxy-D-glucose. Radiology 1995, 197, 205-211.
15. Maier JG, Sulak MH. Radiation therapy in malignant testis tumors: II. Non-seminoma. Cancer 1973, 32, 1212.
16. 18F)fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986, 27, 235-238.
17. Spinks TJ, Jones T, Gilardi MC, Heather JD. Physical performance of the latest generation of commercial positron scanners. IEEE Trans Nucl Sci 1988, 35, 721-725.
18. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-(F-18)-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995, 196, 167-173.
19. Woodward HW, Bigler RB, Freed B, Russ G. Expression of tissue isotope distribution. J Nucl Med 1975, 16, 958-959.
20. Stephens A, Gonin R, Hutchins G, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumors. J Clin Oncol (5) 1996, 14, 1637-1641.
21. 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med (6) 1995, 22, 508-513.
22. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992, 33, 1972-1980.
23. Alavi A, Buchpiguel C, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis? J Nucl Med (10) 1994, 35, 1650-1652.
24. Dohmen BM, Bares R, Gronimus R, et al. Improved staging of germ cell cancer after chemotherapy by FDG-positron-emission-tomography (PET). Eur J Nucl Med (8) 1995, 22, 804.
25. Wahl R, Greenough R, Clarke M, Grossman H. Initial evaluation of FDG/PET imaging of metastatic testicular neoplasms. J Nucl Med 1993, abstract book, 6P.
26. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989, 170, 329-332.
27. Keyes JW. SUV: Standard uptake or silly useless value? J Nucl Med 1995, 36, 1836-1839.
28. Wu HS, Hoh CK, Huang SC, Yao WJ, Phelps ME, Hawkins RA. Quantification of serial tumor glucose metabolism. J Nucl Med (3) 1996, 37, 506-513.